The following is a summary of the EDAP TMS S.A. (EDAP) Q2 2024 Earnings Call Transcript:
Financial Performance:
EDAP TMS S.A. reported Q2 2024 worldwide revenue of $15.8 million, up 10.6% year-over-year.
Gross profit for Q2 2024 was EUR5.9 million, with a gross profit margin of 37.5%, down from 39.6% year-over-year.
Business Progress:
EDAP placed five Focal One systems in notable institutions including City of Hope and Robert Wood Johnson University Hospital.Strong growth in U.S. Focal One HIFU procedures, with a 63% increase year-over-year.
Two operating leases were converted into full cash sales, confirming the market validation of Focal One technology.
Significant academic and scientific presentation of the HIFI study supporting Focal One technology.
Opportunities:
Expansion into additional National Cancer Institute-designated centers and VA healthcare systems.
Potential for further adoption following positive outcomes from the HIFI study.
Risks:
Global economic conditions impacting capital expenditure decisions in hospitals, making the sales cycle longer.
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
